Abstract
Since the controversy over rofecoxib (Vioxx), uncertainty has persisted about the relative cardiac risks of selective cyclo-oxygenase-2 (COX-2)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have